<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of AIDS-related cytomegalovirus retinitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of AIDS-related cytomegalovirus retinitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of AIDS-related cytomegalovirus retinitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Jacobson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Heiden, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acquired immunodeficiency syndrome (AIDS)-related cytomegalovirus (CMV) retinitis is one of the most serious ocular complications in individuals with AIDS. It can progress to blindness, and in some cases, be accompanied by potentially fatal systemic disease. It is typically caused by reactivation of latent disease. CMV retinitis can be prevented by initiating antiretroviral therapy (ART) early in the course of human immunodeficiency virus (HIV) infection. However, CMV retinitis is still seen in patients who do not have access to these medications and/or are unable to adhere to their ART regimen. </p><p>The treatment of CMV retinitis will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of CMV retinitis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis"</a>.)</p><p class="headingAnchor" id="H715106935"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>For patients who develop AIDS-related CMV retinitis, treatment consists of CMV antiviral therapy and antiretroviral therapy (ART) for HIV. In high-income settings, we suggest starting ART approximately two weeks after starting therapy to treat CMV [<a href="#rid1">1</a>]. However, if there are concerns about follow-up (eg, patients who are unlikely to follow up with medical care, patients in resource-limited settings), ART should be initiated immediately. (See <a class="local">'When to initiate antiretroviral therapy'</a> below and <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p>Antiviral treatment options for CMV retinitis include systemic and/or intravitreal therapy. Our approach to treatment is consistent with guideline recommendations  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with newly diagnosed infection, we first assess the location of the lesions (central versus peripheral) and if the patient has immediate sight-threatening disease (lesions &lt;1500 microns from the fovea or adjacent to the optic nerve head). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with immediate sight-threatening lesions, we recommend initial therapy with local intravitreal injections in conjunction with systemic therapy. Treatment should be started as soon as possible [<a href="#rid1">1</a>]. (See <a class="local">'Disease that is immediately sight threatening'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without immediately sight-threatening disease, we recommend systemic therapy alone. (See <a class="local">'Disease that is NOT immediately sight threatening'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The choice of which antiviral agents to use depends in part upon the individual’s ability to take oral medications, the presence of comorbid conditions, their concomitant medications, and their ability to adhere to treatment. Other factors that impact the choice of treatment include the diagnostic capacity to determine the severity of disease, the availability of oral antiviral agents, and/or skilled providers to perform intravitreal injections. (See <a class="local">'Systemic therapy'</a> below and <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with relapsed infection, we typically suggest dual therapy with IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (or oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>) plus IV <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>, unless ART has only recently been initiated, in which case further immune reconstitution may be expected and reinduction with monotherapy valganciclovir or foscarnet may well suffice. (See <a class="local">'Salvage therapy'</a> below.)</p><p></p><p>Initial induction therapy is typically administered until retinitis has become inactive (usually two to three weeks). It is then followed by lower-dose maintenance therapy. (See <a class="local">'Duration of induction therapy'</a> below and <a class="local">'Maintenance therapy for initial infection'</a> below and <a class="local">'Discontinuing maintenance therapy'</a> below.)</p><p>Patients should be monitored closely on treatment to evaluate response to therapy and drug-induced complications  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). Patients should then continue to be monitored, even after they have been successfully treated for CMV retinitis, to evaluate for the onset of significant intraocular inflammation secondary to an immune reconstitution inflammatory syndrome. (See <a class="local">'Patient monitoring'</a> below and <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> below.)</p><p class="headingAnchor" id="H446525483"><span class="h1">INDUCTION THERAPY FOR INITIAL INFECTION</span></p><p class="headingAnchor" id="H446525490"><span class="h2">Disease that is immediately sight threatening</span><span class="headingEndMark"> — </span>We recommend a combination of intravitreal therapy plus systemic therapy for patients with immediate sight-threatening disease (lesions located &lt;1500 microns from the fovea or adjacent to the optic nerve head)  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). Treatment should be administered as soon as possible. We use intravitreal therapy for such patients since it may take several days to achieve steady state intraocular drug levels with systemic therapy. There are no well-designed clinical trials evaluating the use of intravitreal therapy plus systemic therapy for patients with immediate sight-threatening disease. Although infection may be controlled with systemic therapy alone, we administer both modalities to minimize the risk of disease progression given the high risk of clinically significant vision loss.</p><p class="headingAnchor" id="H446525662"><span class="h3">Intravitreal therapy</span><span class="headingEndMark"> — </span>Intravitreal therapy should be used in conjunction with systemic therapy for patients with immediate sight-threatening disease (see <a class="local">'Systemic therapy'</a> below). Either <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> can be injected directly into the eye to achieve high drug levels. Several different regimens can be used [<a href="#rid1">1-3</a>]. We administer intravitreal injections of ganciclovir (2.5 mg in 0.05 ml volume) weekly for two to three injections. We prefer this formulation of intraocular ganciclovir, rather than one that requires a larger volume, to minimize the risk of increased ocular pressure. Foscarnet (2.4 mg/injection) can also be administered as intraocular therapy and should be given twice weekly for 1 to 4 doses over a period of 7 to 14 days. Potential adverse events related to intraocular injections include endophthalmitis, vitreous hemorrhage, and retinal detachment [<a href="#rid4">4</a>]. </p><p>If systemic therapy is initiated within 24 hours of the initial intravitreal injection, subsequent injections are probably unnecessary. In addition, injections can be stopped as soon as the retinal opacity resolves, regardless of how many injections have been given. </p><p>The use of intravitreal therapy is supported by small non-randomized studies that found intravitreal injections with either <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> were effective treatment for CMV retinitis [<a href="#rid5">5</a>]. In addition, well-designed randomized trials demonstrated ganciclovir implants were better than intravenous (IV) ganciclovir as initial therapy [<a href="#rid6">6,7</a>]. As an example, in a randomized trial of 188 patients with AIDS and newly diagnosed cytomegalovirus retinitis, the median time to progression of retinitis ranged from 191 to 221 days in those who received implants (depending upon the dose) versus 71 days in those who received IV ganciclovir [<a href="#rid7">7</a>]. However, ganciclovir implants are no longer being manufactured, and as such, are no longer a treatment option. </p><p class="headingAnchor" id="H446525724"><span class="h3">Systemic therapy</span><span class="headingEndMark"> — </span>We prefer oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> for systemic therapy, rather than IV therapy, given its good oral bioavailability, ease of administration, and the reduced risk of complications or toxicity from an indwelling venous catheter. However, several other systemic therapy options (ie, IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, IV <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>, IV <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>) are available. The choice depends in part on the patient’s ability to tolerate the individual agents. The antiviral agents used to treat CMV may require dose modifications for renal impairment; detailed dosing recommendations are available in the individual drug information monographs included within UpToDate and the individual topic reviews. (See  <a class="medical medical_review" href="/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview"</a> and  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview"</a> and  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> — Valganciclovir is an orally administered prodrug of <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>. Valganciclovir is given at doses of 900 mg twice daily with food for the first 14 to 21 days of induction therapy. Oral bioavailability is approximately 60 percent and is 10-fold higher than that with oral ganciclovir [<a href="#rid8">8</a>]. Its oral formulation offers cost savings and the advantage of avoiding catheter-related complications associated with chronic intravenous therapies [<a href="#rid9">9</a>]. The toxicity profile of valganciclovir is identical to that of IV ganciclovir and is mainly related to its effect on bone marrow suppression [<a href="#rid10">10</a>]. (See <a class="local">'Adverse reactions'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">Valganciclovir</a> was found to be as effective as IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> for induction therapy of CMV retinitis in a multicenter randomized trial of 160 patients with AIDS and newly diagnosed CMV retinitis [<a href="#rid11">11</a>]. Although this study excluded patients with lesions located &lt;1500 microns from the fovea or adjacent to the optic nerve head, we believe that the results can be extrapolated to those with immediate sight-threatening disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV </strong><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a><strong> or IV </strong><a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> — IV ganciclovir or foscarnet can be used for the treatment of CMV retinitis in individuals who are unable to tolerate oral therapy [<a href="#rid12">12,13</a>]. These agents were widely used prior to the introduction of oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>. The only trial comparing IV ganciclovir and IV foscarnet for the treatment of CMV retinitis was a randomized, unblinded trial conducted in 234 patients with AIDS, and the two agents demonstrated equivalent efficacy [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1">The induction doses are as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a> 5 mg/kg/dose every 12 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">Foscarnet</a> 60 mg/kg/dose every eight hours, or 90 mg/kg/dose every 12 hours</p><p></p><p class="bulletIndent1">We generally prefer <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> rather than <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> for initial therapy as it is easier to administer and is generally better tolerated. We administer foscarnet to individuals who have adverse reactions to oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> or IV ganciclovir, as well as those who are at risk for complications from ganciclovir (eg, patients with an absolute neutrophil count &lt;500 cells/microL or a platelet count &lt;20,000 cells/microL). The main adverse events of ganciclovir are hematologic; those of foscarnet are mainly related to renal toxicity and electrolyte disturbances. (See <a class="local">'Adverse reactions'</a> below and  <a class="medical medical_review" href="/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview"</a> and  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> — We administer cidofovir to patients who are unable to tolerate any of the other treatment options (<a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>, <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>). The dose of cidofovir for CMV retinitis is 5/mg/kg/week for two weeks, then 5 mg/kg every other week. <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">Saline</a> hydration and high-dose <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> therapy is given concomitantly with cidofovir to reduce the risk of serious renal injury [<a href="#rid15">15,16</a>]  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> is <strong>contraindicated</strong> in patients with a creatinine &gt;1.5 mg/dL, an estimated glomerular filtration rate ≤55 mL/min/1.73m<sup>2</sup>, or a urine protein ≥100 mg/dL. Serum creatinine, blood urea nitrogen, and urinalysis should be performed before infusions to detect renal dysfunction or proteinuria [<a href="#rid1">1</a>]. In addition, cidofovir should be avoided in patients with a sulfa allergy because of cross hypersensitivity with <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). It should also be avoided in settings where the patient is at high risk for developing an immune reconstitution inflammatory syndrome (eg, patients initiating antiretroviral therapy [ART]) [<a href="#rid17">17</a>], since cidofovir has been associated with immune recovery uveitis [<a href="#rid18">18</a>]. (See <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> is a nucleoside monophosphate analogue with potent in vitro activity against CMV that is 10- to 100-fold greater than that of other anti-CMV drugs. In the pre-ART era, two randomized trials demonstrated the efficacy of cidofovir for the treatment of patients without immediately sight-threatening retinitis [<a href="#rid15">15,16</a>]. Cidofovir was also demonstrated to have utility in the treatment of patients who had failed therapy with <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> [<a href="#rid19">19</a>]. (See <a class="local">'Relapsed infection'</a> below.)</p><p></p><p class="bulletIndent1">However, the use of <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> is quite limited due to its toxicity. Cidofovir can cause serious, irreversible nephrotoxicity via dose-dependent proximal tubular cell injury. Nephrotoxicity or <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> intolerance (eg, fever, nausea, vomiting, rash) is treatment-limiting in approximately one-third to one-half of patients. The initial manifestations of renal toxicity are proteinuria and increased serum creatinine concentrations; with continued treatment, some patients have had a life-threatening Fanconi-like syndrome and renal failure. Neutropenia, peripheral neuropathy, abnormally low intraocular pressure, anterior uveitis, and alopecia have also been reported with cidofovir [<a href="#rid10">10</a>]. (See <a class="local">'Adverse reactions'</a> below.)</p><p></p><p class="bulletIndent1">A more detailed discussion of <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> is found elsewhere. (See  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview"</a>.)</p><p></p><p class="headingAnchor" id="H446525712"><span class="h2">Disease that is NOT immediately sight threatening</span><span class="headingEndMark"> — </span>For patients with disease that is not immediately sight threatening, we recommend systemic therapy alone. Systemic therapy with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>, IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, or IV <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> has been found to be effective in treating CMV retinitis. We prefer oral valganciclovir rather than IV therapy. A detailed discussion on systemic therapy is found above. (See <a class="local">'Systemic therapy'</a> above.)</p><p>Although intravitreal therapy has been successfully used for initial treatment of CMV retinitis in patients without sight-threatening disease (see <a class="local">'Intravitreal therapy'</a> above), we prefer systemic therapy given the limitations of using intraocular injections [<a href="#rid20">20</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>The subsequent development of extraocular CMV disease or contralateral retinitis in patients treated for unilateral disease. Both occur in approximately one-third of patients who are treated with intravitreal therapy alone [<a href="#rid7">7,21,22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No effect on CMV-related mortality [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for patient acceptance and cooperation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential onset of serious adverse events related to intraocular injections (eg, endophthalmitis, vitreous hemorrhage, retinal detachment) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weekly clinic visits, which could be difficult for certain patients. </p><p></p><p>However, in certain resource-limited settings, intraocular <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> injections may be the only viable treatment option. (See <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p class="headingAnchor" id="H461225826"><span class="h1">DURATION OF INDUCTION THERAPY</span><span class="headingEndMark"> — </span>The majority of patients being treated for CMV retinitis will receive systemic therapy. Induction therapy is typically administered for 14 to 21 days. However, the ultimate duration is determined by the patient’s response to therapy (see <a class="local">'Ophthalmologic evaluation'</a> below). On occasion, patients may not have access to systemic therapy and are treated with intravitreal therapy alone. The duration of induction therapy for such patients is described below. (See <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p>After successful induction therapy, patients should transition to maintenance therapy with reduced doses of anti-CMV therapy. (See <a class="local">'Maintenance therapy for initial infection'</a> below.)</p><p class="headingAnchor" id="H446525759"><span class="h1">MAINTENANCE THERAPY FOR INITIAL INFECTION</span><span class="headingEndMark"> — </span>Patients should receive maintenance therapy to reduce the risk of relapse  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). There are no randomized trials to support this approach. However, in a case series of patients with CMV retinitis, relapse occurred in five of seven patients who interrupted <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> maintenance therapy [<a href="#rid24">24</a>] </p><p class="headingAnchor" id="H528853735"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> (900 mg daily) for maintenance therapy. There are no clinical trials comparing the efficacy of valganciclovir with other agents for chronic maintenance therapy of CMV retinitis. However, the <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> area under the curve achieved with 900 mg of oral valganciclovir tablets is equivalent to that achieved with 5 mg/kg of intravenous ganciclovir [<a href="#rid25">25</a>].</p><p>If oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> is not available or not tolerated, the maintenance dose of IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> is 5 mg/kg/day as a single-daily dose for seven days a week or 6 mg/kg/day for five days per week. The maintenance dose of <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> is 90 to 120 mg/kg/day as a single infusion. Individuals receiving <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> should continue on every other week dosing. (See <a class="local">'Systemic therapy'</a> above.)</p><p>A discussion of maintenance therapy in patients without access to systemic therapy is described below. (See <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p class="headingAnchor" id="H528853403"><span class="h2">Discontinuing maintenance therapy</span><span class="headingEndMark"> — </span>We suggest that anti-CMV maintenance therapy be discontinued in patients receiving antiretroviral therapy (ART) for HIV if they meet all of the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>They have quiescent retinitis.</p><p class="bulletIndent1"><span class="glyph">●</span>The lesions have been treated for at least three months with anti-CMV therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>The CD4 count is ≥100 cells/microL for at least three months.</p><p></p><p>The patient's HIV viral load, adherence to ART, and likelihood of immune deterioration in the near future should also be considered in deciding whether to discontinue maintenance therapy. As an example, the authors would not discontinue maintenance therapy if a patient has virologic failure (HIV viral load &gt;200 copies/mL on two consecutive measurements), as that could indicate poor adherence and imminent immune deterioration.</p><p>If maintenance therapy was discontinued, patients whose CD4 counts drop to &lt;100 cells/microL should reinitiate maintenance therapy [<a href="#rid1">1,26,27</a>]. A discussion on discontinuing maintenance therapy in resource-limited settings is found below. (See <a class="local">'Duration of therapy'</a> below.)</p><p>Small observational studies suggest that patients who have sustained CD4 counts ≥100 cells/microL for six months or longer on ART can safely discontinue CMV maintenance therapy without recurrence of CMV retinitis [<a href="#rid28">28-31</a>]. The patients described in these reports generally had CD4 counts that were &lt;50 cells/microL at the time when CMV retinitis was diagnosed, which then increased to &gt;150 cells/microL after initiating potent combination ART regimens. Most of the patients who relapsed had CD4 counts that dropped to &lt;50 cells/microL at the time of relapse.</p><p>It is important to review the symptoms of CMV retinitis when maintenance therapy is discontinued. On occasion, patients with improved CD4 cell counts and viral suppression can still have a relapse of CMV retinitis [<a href="#rid32">32,33</a>]. Although patients may have an increase in the absolute CD4 cell count on ART, they may not have sufficient immune reconstitution of T cell subsets to prevent a recurrence of retinitis. In one study using immunophenotypic markers, patients on ART with a history of prior CMV retinitis had significantly lower numbers of CD4-naïve and memory T cells compared with AIDS patients with a prior history of pneumocystis pneumonia but not CMV retinitis [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H7"><span class="h1">RELAPSED INFECTION</span><span class="headingEndMark"> — </span>Most patients with CMV retinitis who are not treated with (or do not respond to) antiretroviral therapy (ART) for their HIV eventually relapse on maintenance therapy with breakthrough viral reactivation that results in further retinal necrosis. Breakthrough can occur despite continued anti-CMV therapy. Renewed activity is manifested as new retinal lesions, new opacifications, or advancement of the border of old lesions. </p><p class="headingAnchor" id="H528854012"><span class="h2">Reasons for failure</span><span class="headingEndMark"> — </span>Clinical relapses that occur less than three months after anti-CMV therapy is initiated may be due to any of the following factors: </p><p class="bulletIndent1"><span class="glyph">●</span>Absence of ART-mediated immune reconstitution</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Healing of the initial retinal lesions might strengthen the blood-retina barrier and block drug from crossing into the retina and vitreous</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor adherence to anti-CMV medications</p><p></p><p>If an individual relapses after prolonged use of anti-CMV therapy, the relapse may be due to drug-resistant CMV [<a href="#rid8">8</a>]. The presence of drug-resistant virus is associated with an increased risk of progression of CMV retinitis and development of disease in the contralateral eye [<a href="#rid35">35,36</a>]. Risk factors for drug resistance include inadequate drug concentrations and frequent discontinuation of therapy. </p><p>However, the incidence of CMV resistance in patients with HIV has declined since the introduction of potent ART. As an example, in one prospective observational study of 257 patients with CMV retinitis, the incidence of drug resistance decreased from 28 percent prior to 1996, to 9 percent after 1996 [<a href="#rid37">37</a>]. In this study, all cases of resistance occurred among patients with CD4 counts &lt;50 cells/microL; in addition, CMV-positive blood cultures at baseline were associated with a fourfold risk of developing resistance. </p><p class="headingAnchor" id="H528854316"><span class="h2">Evaluation for drug resistance</span><span class="headingEndMark"> — </span>Patients with a detectable CMV viral load in the blood can be assessed for the presence of drug-resistant virus. Vitreal aspirates can also be assessed for drug-resistant virus in patients with active CMV retinitis. Drug resistance generally results from alterations in two different viral genes, namely the phosphotransferase gene (pUL97) and the viral deoxyribonucleic acid (DNA) polymerase gene (pUL54). Low-level <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> resistance is due to mutations in the UL97 gene; high-level resistance is due to mutations in both UL97 and UL54 genes [<a href="#rid38">38</a>]. </p><p>Genotypic testing is the best way to assess for the presence of resistance since these assays can be completed within a few days if testing is performed directly on blood rather than culture isolates [<a href="#rid39">39</a>]. Genotypic resistance is defined by the presence of a mutation known to confer resistance [<a href="#rid40">40</a>]. An alternative approach is a phenotypic assay, where resistance is measured by the ability of CMV to grow in the presence of an anti-CMV drug. However, phenotypic assays are not well standardized and take four weeks to perform; thus, they are not practical for clinical use</p><p>Genotyping of CMV can be accomplished by directly amplifying the UL97 gene from blood specimens via polymerase chain reaction (PCR) in less than 48 hours. A prospective study of 845 paired specimens was conducted to compare direct PCR amplification of blood specimens to culture isolates for accuracy in susceptibility testing and their association with progression of CMV retinitis [<a href="#rid40">40</a>]. The study demonstrated the following results:</p><p class="bulletIndent1"><span class="glyph">●</span>There was &gt;90 percent agreement in the genotypic results of direct amplification of blood specimens compared with culture isolates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agreement between phenotypic resistance and the detection of UL97 mutations was &gt;92 percent for PCR-amplified blood specimens and &gt;97 percent for culture isolates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression of retinitis correlated with the detection of UL97 mutations in PCR-amplified blood specimens (odds ratio 7.0 for leukocytes, 9.0 for plasma) and for culture isolates (odds ratio 18.0).</p><p></p><p>Although blood culture results were the strongest predictor of progression of CMV retinitis, the much faster results obtained with direct PCR amplification of CMV DNA in blood supports the clinical utility of this approach. </p><p class="headingAnchor" id="H528854006"><span class="h2">Salvage therapy</span><span class="headingEndMark"> — </span>For most patients who relapse on maintenance therapy, we suggest IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (or oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>) plus IV <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). However, if a patient does <strong>not</strong> have immediately sight-threatening disease, and only recently initiated ART, we would re-administer induction therapy using the same agent they previously received.</p><p>Combination therapy is the only salvage treatment strategy supported by clinical trial data. In a randomized, controlled trial of salvage therapy for patients with AIDS and relapsed CMV retinitis, patients were randomized to one of three regimens [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (induction with 5 mg/kg IV every 12 hours for two weeks followed by maintenance at 10 mg/kg per day)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (induction with 90 mg/kg IV every 12 hours for two weeks followed by maintenance at 120 mg/kg per day)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuation of previous therapy plus induction with the other drug (either <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>) for two weeks followed by standard maintenance doses of both ganciclovir (5 mg/kg per day) and foscarnet (90 mg/kg per day)</p><p></p><p>The combined regimen was twice as effective as either drug alone, delaying time to further progression: 1.3 months with <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>; 2.0 months with <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>; and 4.3 months with combination therapy. Several other visual outcome measures (rate of visual field loss and change in amount of retinal area involved by CMV) were also significantly better in patients given the combination regimen. However, cross-resistance to the different antiviral agents used to treat CMV may be present [<a href="#rid42">42</a>], and some patients may not respond to salvage therapy.</p><p>For patients who cannot tolerate dual therapy, we administer monotherapy with a different agent (eg, <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> for patients who started on <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>). We do not use <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> unless the patient cannot tolerate and/or fails all of the other treatment options. Fomivirsen, an antisense oligonucleotide, was used in the past for salvage therapy, but is no longer manufactured [<a href="#rid43">43-46</a>].</p><p>In addition to systemic therapy, there is anecdotal experience that local therapy may be effective, with weekly intravitreal injection of <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> in a dose of 2.5 mg (or 5 mg) in 0.05 mL volume, until active retinitis has resolved.</p><p>For patients who have either clinical or virologic resistance or intolerance to the agents approved for treatment of CMV retinitis, newer anti-CMV agents (<a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a> and <a class="drug drug_general" data-topicid="134463" href="/d/drug information/134463.html" rel="external">maribavir</a>) can be considered. However, these agents have only been studied in transplant populations, and in these populations, there is only very limited experience treating CMV retinitis. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"</a> and  <a class="medical medical_review" href="/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p><a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">Letermovir</a> is a CMV viral terminase complex inhibitor that is used for prophylaxis of CMV disease in allogeneic hematopoietic stem cell transplantation (HSCT) recipients and may also have a role for treatment of CMV viremia in solid organ transplant recipients. In one report, letermovir was used for salvage treatment in four solid organ transplant recipients who had documented ganciclovir-resistant CMV retinitis [<a href="#rid47">47</a>]. While all four patients improved clinically, only one had CMV viremia suppressed, and the clinical outcome may have been impacted by the concomitant use of intravitreal <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> injections [<a href="#rid48">48</a>] or changes in immunosuppressive therapy. If letermovir is being considered for patients with HIV, it can have problematic drug interactions with several non-nucleoside reverse transcriptase and protease inhibitor antiretroviral drugs used for HIV treatment, as well as all rifamycins used to treat tuberculosis.</p><p><a class="drug drug_general" data-topicid="134463" href="/d/drug information/134463.html" rel="external">Maribavir</a> is a CMV UL97 gene product inhibitor that has been studied as a treatment for refractory or drug-resistant CMV infection in solid organ transplant and HSCT recipients. Clinical and virologic responses have been reported in these transplant populations, and in the United States, the Food and Drug Administration has granted expanded access status for this drug. There have been no reports describing the use of maribavir for treating CMV retinitis.</p><p class="headingAnchor" id="H10"><span class="h1">PATIENT MONITORING</span><span class="headingEndMark"> — </span>Management of CMV retinitis requires close monitoring by an experienced ophthalmologist and the HIV provider. </p><p class="headingAnchor" id="H446526571"><span class="h2">Ophthalmologic evaluation</span><span class="headingEndMark"> — </span>Dilated indirect ophthalmoscopy should be performed after two weeks of induction therapy, and monthly thereafter while the patient is on anti-CMV treatment [<a href="#rid1">1</a>]. Monthly fundus photographs are optimal for detecting early relapse. </p><p>Certain patients should have additional monitoring.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with immediately sight-threatening retinitis, some clinicians perform weekly dilated retinal exams until there is evidence of healing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> should be evaluated for decreased intraocular pressure with slit lamp examination of the anterior chamber and tonometry. (See <a class="local">'Adverse reactions'</a> below.)</p><p></p><p>Patients who have been successfully treated for CMV retinitis need ongoing ophthalmologic examinations to monitor for the onset of intraocular inflammation secondary to an immune reconstitution inflammatory syndrome. Monitoring at three-month intervals is appropriate with progressively longer intervals over time. Patients should be instructed to call immediately should visual symptoms recur. A discussion on the different immune recovery syndromes is found below. (See <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> below.) </p><p class="headingAnchor" id="H446526577"><span class="h2">Adverse reactions</span><span class="headingEndMark"> — </span>The laboratory monitoring and dose-limiting toxicities of the agents used to treat CMV retinitis are summarized in the table  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). For patients receiving anti-CMV therapy, several interventions may help reduce or prevent the adverse reactions seen with these agents. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a> and <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> have been associated with bone marrow suppression. Granulocyte-colony stimulating factor (G-CSF) is well tolerated and can be used to facilitate dosing of ganciclovir and valganciclovir; it can also reduce the risk of bacterial infections [<a href="#rid49">49-51</a>]. Subcutaneous administration of G-CSF (10 mcg/kg/day) can be administered to patients with an absolute neutrophil count (ANC) &lt;500 cells/microL with a target to keep the ANC in the 500 to 1000 cell range. Complete blood counts with differentials should be drawn just prior to the next dose of growth factor.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a> can also result in thrombocytopenia. For such patients with a platelet count &lt;20,000/mm<sup>3</sup>, we discontinue treatment and switch to an alternative agent (eg, <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">Foscarnet</a> is associated with renal toxicity and electrolyte abnormalities, including infusion–related decreases in ionized calcium. To minimize these risks, patients should receive concomitant <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (generally 0.5 to 1 L) with each dose of foscarnet. In addition, electrolytes (calcium, magnesium, phosphate, potassium) should be monitored twice weekly during induction therapy and weekly during maintenance therapy, and replaced as necessary. (See  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview", section on 'Toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> and intravenous fluids should be administered to decrease the risk of nephrotoxicity. (See <a class="local">'Systemic therapy'</a> above and  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview", section on 'Toxicity'</a>.)</p><p></p><p>Additional discussions of the potential side effects are found elsewhere. (See  <a class="medical medical_review" href="/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview"</a> and  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview"</a> and  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview"</a>.)</p><p class="headingAnchor" id="H101636402"><span class="h1">WHEN TO INITIATE ANTIRETROVIRAL THERAPY</span><span class="headingEndMark"> — </span>Patients may already be on antiretroviral therapy (ART) when they are diagnosed with CMV retinitis. For such patients, ART should not be interrupted. However, many patients with CMV retinitis are not on ART. The timing of when to initiate ART in the setting of CMV retinitis is not clear because the benefit of immune recovery must be weighed against the risk of developing an immune reconstitution inflammatory syndrome (IRIS). (See <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> below.)</p><p>For patients in high-income settings, we suggest ART be initiated approximately two weeks after initiating therapy to treat CMV [<a href="#rid1">1</a>]. However, in resource-limited settings, ART should be initiated immediately because the high early mortality risk (due in part to concurrent infections other than CMV and extraocular CMV disease) generally outweighs the risk of developing IRIS. A discussion on the management of patients with CMV retinitis in resource-limited settings is found below. (See <a class="local">'Treatment in resource-limited settings'</a> below.)</p><p>Studies evaluating ART initiation include a case-historical control study, where the risk of developing immune recovery uveitis was greater in patients starting ART at the same time as anti-CMV therapy compared with those who delayed initiation of ART [<a href="#rid52">52</a>]. However, lack of immune recovery in patients with CMV retinitis can increase the risk of progressive CMV disease and retinal detachment with subsequent vision loss [<a href="#rid53">53</a>]. (See <a class="local">'Relapsed infection'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h1">CMV IMMUNE RECONSTITUTION INFLAMMATORY SYNDROMES</span><span class="headingEndMark"> — </span>After initiation of antiretroviral therapy (ART) for HIV, patients with CMV retinitis may develop significant intraocular inflammation secondary to an immune reconstitution inflammatory syndrome (IRIS) [<a href="#rid4">4,54</a>]. ART should not be stopped in the setting of IRIS given the importance of immune recovery, but anti-inflammatory therapy may provide some benefit as described below. Thus, any patient with HIV with new visual symptoms after initiation of ART should be referred promptly for ophthalmic examination. The pathogenesis of IRIS is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>The IRIS syndrome associated with CMV retinitis is referred to as immune recovery uveitis (IRU). It can become clinically apparent any time after initiation of ART, ranging from weeks to years, and can manifest even when CMV retinitis is completely inactive. The initial inflammatory response occurs when immunity is restored [<a href="#rid55">55</a>], then wanes as retinitis becomes inactive, although persistent low-grade inflammation and complications can persist for years. Patients can present clinically with vitritis or other manifestations of uveitis, such as anterior chamber inflammation with posterior synechiae, cystoid macular edema, epiretinal membrane formation, or cataract. This condition can lead to significant ocular morbidity [<a href="#rid18">18,53,56-58</a>]. </p><p>The clinical manifestations of IRIS associated with CMV retinitis are due to inflammation and not drug failure. Thus, we do not modify the dose of the anti-CMV agent (typically <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>) if patients are receiving maintenance therapy. In addition, we do not restart <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or valganciclovir in patients with CMV-IRU if they have completed anti-CMV therapy and are <strong>without</strong> evidence of CMV reactivation [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis", section on 'Clinical manifestations'</a>.)</p><p>The benefit of anti-inflammatory treatment for CMV-IRU has received limited systematic study. Uncontrolled treatment studies with anti-CMV therapy or glucocorticoids have not provided convincing evidence that either intervention is beneficial in patients with CMV-IRU [<a href="#rid38">38,61-63</a>]. However, given the severe consequences of CMV-IRU, we use the following approach to manage inflammation:</p><p class="bulletIndent1"><span class="glyph">●</span>We administer treatment to reduce inflammation in patients with vitritis and/or macular edema when the visual acuity is reduced and vision is symptomatically compromised with blurred vision. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We first initiate topical glucocorticoids (eg, <a class="drug drug_general" data-topicid="9018" href="/d/drug information/9018.html" rel="external">difluprednate</a> one drop four times per day) for six weeks. The intraocular pressure should be measured at four to six weeks; if above the normal range, glaucoma drops can be added, or glucocorticoid therapy reduced or discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If, at six weeks, there has been inadequate clinical improvement of vitritis or macular edema with topical glucocorticoids, and there has been no evidence of secondary glaucoma, we switch to posterior sub-tenons glucocorticoid injections (eg, 1 mL of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> [40 mg/mL] every four to six months). Intraocular pressure should continue to be monitored monthly during this period. Treatment is continued as long as symptoms of IRU persist and intraocular pressures remain adequately controlled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical intervention for cataract removal is commonly needed in patients with IRU within several years. Less commonly, there may be need for vitrectomy for patients who develop epiretinal membranes or fail to clear vitreous inflammation.</p><p></p><p class="headingAnchor" id="H992685081"><span class="h1">TREATMENT IN RESOURCE-LIMITED SETTINGS</span></p><p class="headingAnchor" id="H2767726733"><span class="h2">Prevention of end-organ disease</span><span class="headingEndMark"> — </span>CMV retinitis continues to be a cause of blindness among patients with AIDS in resource-limited settings [<a href="#rid20">20,64-67</a>]. In retrospective analyses of 94 patients from Myanmar [<a href="#rid68">68</a>] and 91 patients from South Africa [<a href="#rid69">69</a>] with CMV retinitis, 45 and 42 percent of patients, respectively, either died or were lost to follow-up within a year. </p><p>Since lack of diagnostic capacity continues to be a central problem in the management of this disease in resource-limited settings, prevention of CMV end-organ disease should be part of the management of patients with very advanced HIV disease in such countries. Virologic screening with CMV RNA in patients with low CD4 counts at the time of initiation of antiretroviral therapy [ART] may help detect viremic patients prior to the development of clinical CMV end-organ disease and allow for systemic pre-emptive treatment of CMV viremia. Systemic pre-emptive treatment of CMV viremia may soon be feasible with the availability of generic <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> formulations. </p><p>A report suggests that clinical CMV end-organ disease can be identified in advance by virologic monitoring. In a large prospective case series from India, a serum CMV viral load &gt;5.4 log<sup>10</sup>DNA/mL, as measured by polymerase chain reaction assay, was associated with the development of clinical CMV end-organ disease [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H2155253472"><span class="h2">Antiviral regimens</span><span class="headingEndMark"> — </span>Early diagnosis and anti-CMV therapy is the best way to prevent CMV-related complications (eg, retinal detachment and immune recovery uveitis [CMV-IRU]). In addition, in resource-limited settings, ART for HIV should be initiated immediately because the high early mortality risk generally outweighs the risk of developing a CMV-IRU. This is in contrast to high-income settings where ART is initiated approximately two weeks after anti-CMV induction therapy because such patients are typically monitored more closely and receive better supportive care for concurrent infections other than CMV. Additional discussions on initiating ART and immune reconstitution syndromes are found above. (See <a class="local">'When to initiate antiretroviral therapy'</a> above and <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> above.) </p><p>Treatment for CMV retinitis should include systemic therapy with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> [<a href="#rid71">71</a>]. However, several issues impact the approach to treatment in resource-limited settings: it may be difficult to determine the severity of CMV retinitis (eg, whether or not sight-threatening disease is present or absent); there are limited options for managing toxicity to initial therapy (eg, granulocyte stimulating factor to treat neutropenia); and alternative systemic antiviral agents such as <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> are typically not available. (See <a class="local">'Adverse reactions'</a> above and <a class="local">'Systemic therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the severity of the disease can be adequately determined:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients without sight-threatening disease should receive <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg twice daily for 14 to 21 days and then transition to 900 mg once daily. Unlike high-income settings, the transition to maintenance therapy is typically based upon protocol and not exam findings. As of April 2015, this medication is included in the 19th World Health Organization Model list of essential medications [<a href="#rid72">72</a>]. (See <a class="local">'Systemic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with sight-threatening disease (lesions located &lt;1500 microns from the fovea or adjacent to the optic nerve head) should receive systemic therapy with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> (as above) in conjunction with intravitreal injections. A detailed discussion of treatment for sight-threatening disease is found above. (See <a class="local">'Disease that is immediately sight threatening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In resource-limited settings, patients typically present with advanced retinitis. Thus, if there is limited diagnostic capacity to discriminate between immediate sight-threatening and other categories of disease, it may be reasonable to administer intravitreal <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> injections for induction therapy (2.5 mg in 0.05 mL volume weekly for two to three injections), in combination with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>. In addition, certain health care systems may function more successfully with a consistent treatment protocol. </p><p></p><p>Prior to initiating therapy, we obtain baseline laboratories, including a complete blood count, platelets, and creatinine. For those with an estimated glomerular filtration rate (eGFR) between 10 and 59 mL/min/1.73m<sup>2</sup>, the dose of <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> can be reduced as described in the Lexi drug monograph within UpToDate. </p><p>We <strong>avoid</strong> systemic therapy and use intravitreal injections alone for:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with neutrophils ≤500 cells/microL, a platelet count ≤20,000/microL, or a hemoglobin &lt;8 g/dL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with an eGFR of &lt;10 mL/min/1.73m<sup>2</sup> </p><p></p><p>Intravitreal therapy alone may also be used in patients who need to discontinue systemic therapy with <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> because of neutropenia (≤500 cells/microL), thrombocytopenia (≤20,000/microL), severe anemia (&lt;8 g/dL), or an eGFR&lt;10 mL/min/1.73m<sup>2</sup>. For patients receiving oral valganciclovir, a complete blood count, platelets, and creatinine should be obtained at a minimum of two weeks after starting therapy and then monthly over the course of treatment. Labs should be monitored more frequently if possible as described in the table  (<a class="graphic graphic_table graphicRef80535" href="/d/graphic/80535.html" rel="external">table 1</a>). </p><p>Patients initiating therapy with intraocular injections alone require injections weekly until treatment can be discontinued (see <a class="local">'Duration of therapy'</a> below). Although lack of medical personnel trained in this technique may be a barrier to treatment, primary care clinicians can be trained to administer intravitreal injections [<a href="#rid73">73</a>]. This is particularly important in areas where <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> is not available (eg, because of cost). A discussion of the limitations of intraocular therapy is found above. (See <a class="local">'Disease that is NOT immediately sight threatening'</a> above.) </p><p class="headingAnchor" id="H1561287820"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of therapy for CMV retinitis in resource-limited settings is independent of the type of treatment (eg, systemic or intravitreal alone), and we extend treatment until <strong>all</strong> three of the following conditions are met [<a href="#rid74">74</a>]: </p><p class="bulletIndent2"><span class="glyph">•</span>Patients have received anti-CMV therapy for a minimum of three months </p><p class="bulletIndent2"><span class="glyph">•</span>Active CMV retinitis has completely resolved</p><p class="bulletIndent2"><span class="glyph">•</span>The patient has received ART for at least three months and has achieved a CD4 count ≥100 cells/microL or a CD4 count that has increased by &gt;50 cells/microL above baseline</p><p></p><p>Although these recommendations are similar to those in high-income settings, the criteria for immunologic recovery prior to discontinuing treatment is less stringent. (See <a class="local">'Discontinuing maintenance therapy'</a> above.)</p><p class="headingAnchor" id="H125445753"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>AIDS-related cytomegalovirus (CMV) retinitis is one of the most serious ocular complications in individuals with AIDS, and it can progress to sight-threatening or systemic disease. Although CMV retinitis can be prevented by initiating antiretroviral therapy (ART) early in the course of HIV infection, this disease is still seen in patients who do not have access to these medications and/or are unable to adhere to their ART regimen. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients <strong>with</strong> immediately sight-threatening lesions, we recommend initial therapy with an immediate intravitreal injection of <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> or <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> plus systemic therapy for CMV rather than systemic therapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Criteria for sight-threatening lesions are lesions &lt;1500 microns from the fovea or adjacent to the optic nerve head. If systemic therapy is initiated within 24 hours of the initial intravitreal injection, subsequent injections are probably not necessary. (See <a class="local">'Disease that is immediately sight threatening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients <strong>without</strong> immediately sight-threatening CMV retinitis, we recommend systemic therapy rather than local therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> is as effective as intravenous therapy and is therefore typically the preferred systemic therapy. (See <a class="local">'Disease that is NOT immediately sight threatening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction therapy with systemic antiviral medications is typically administered for 14 to 21 days. However, the ultimate duration is determined by the patient’s response to therapy. After successful induction therapy, patients should transition to maintenance therapy with reduced doses of anti-CMV therapy. (See <a class="local">'Duration of induction therapy'</a> above and <a class="local">'Maintenance therapy for initial infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilated indirect ophthalmoscopy should be performed two weeks after initiating therapy. For patients with immediately sight-threatening disease, some clinicians perform weekly dilated retinal exams until there is evidence of healing. Patients should be followed monthly thereafter while the patient is on anti-CMV treatment; fundus photographs obtained at these visits are optimal for detecting early relapse. (See <a class="local">'Patient monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in high-income settings who are not already on ART, we suggest that ART be started approximately two weeks after initiating CMV therapy rather than starting concurrently with CMV therapy or delaying therapy significantly longer than two weeks (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, in resource-limited settings, ART should be initiated immediately. (See <a class="local">'When to initiate antiretroviral therapy'</a> above and <a class="local">'Treatment in resource-limited settings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV maintenance therapy can be discontinued in patients who are on ART if they meet all of the following criteria: received anti-CMV therapy for at least three months, have quiescent retinitis, and have a CD4 count ≥100 cells/microL for at least three months. However, the patient's HIV viral load and adherence to ART should also be considered when making this decision so CMV therapy is not stopped in patients who are at risk for immune deterioration in the near future. If maintenance therapy is discontinued, it should be restarted if the CD4 count subsequently drops below 100 cells/microL. (See <a class="local">'Discontinuing maintenance therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any patient who develops vision loss, visual blurring, floaters, or ocular pain on CMV therapy should be evaluated by an ophthalmologist to determine if these symptoms are related to CMV progression, relapse, retinal detachment, or an immune reconstitution inflammatory syndrome (eg, CMV immune recovery uveitis). ART should not be stopped in the setting of IRIS given the importance of immune recovery, but anti-inflammatory therapy may provide some benefit. (See <a class="local">'CMV immune reconstitution inflammatory syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients who relapse on maintenance therapy, we suggest IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (or oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>) plus <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). However, if a patient does <strong>not</strong> have immediately sight-threatening disease, and only recently initiated ART, we would re-administer induction therapy using the same agent they previously received. (See <a class="local">'Relapsed infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In resource-limited settings, the treatment of CMV retinitis should include systemic therapy with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>. However, several issues may impact the approach to treatment: it may be difficult to determine the severity of CMV retinitis; there are limited options for monitoring and managing toxicity to initial therapy; and in some areas, valganciclovir may not be available. (See <a class="local">'Treatment in resource-limited settings'</a> above.)</p><p></p><p class="headingAnchor" id="H198448798"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on April 12, 2022).</li><li><a class="nounderline abstract_t">Arevalo JF, Garcia RA, Mendoza AJ. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Eur J Ophthalmol 2005; 15:610.</a></li><li><a class="nounderline abstract_t">Teoh SC, Ou X, Lim TH. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Ophthalmology 2012; 119:588.</a></li><li><a class="nounderline abstract_t">Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008; 145:397.</a></li><li><a class="nounderline abstract_t">Smith CL. Local therapy for cytomegalovirus retinitis. Ann Pharmacother 1998; 32:248.</a></li><li><a class="nounderline abstract_t">Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994; 112:1531.</a></li><li><a class="nounderline abstract_t">Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997; 337:83.</a></li><li><a class="nounderline abstract_t">Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873.</a></li><li><a class="nounderline abstract_t">Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859.</a></li><li><a class="nounderline abstract_t">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a class="nounderline abstract_t">Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.</a></li><li><a class="nounderline abstract_t">Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6:515.</a></li><li><a class="nounderline abstract_t">Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665.</a></li><li><a class="nounderline abstract_t">Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213.</a></li><li><a class="nounderline abstract_t">Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126:257.</a></li><li><a class="nounderline abstract_t">Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997; 126:264.</a></li><li><a class="nounderline abstract_t">Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.</a></li><li><a class="nounderline abstract_t">Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006; 113:684.</a></li><li><a class="nounderline abstract_t">Lalezari JP, Holland GN, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:339.</a></li><li><a class="nounderline abstract_t">Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.</a></li><li><a class="nounderline abstract_t">Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063.</a></li><li><a class="nounderline abstract_t">Yust I, Fox Z, Burke M, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23:550.</a></li><li><a class="nounderline abstract_t">Jabs DA, Ahuja A, Van Natta M, et al. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2013; 120:1262.</a></li><li><a class="nounderline abstract_t">Jabs DA, Newman C, De Bustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94:824.</a></li><li><a class="nounderline abstract_t">Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37:167.</a></li><li><a class="nounderline abstract_t">Song MK, Karavellas MP, MacDonald JC, et al. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 2000; 20:151.</a></li><li><a class="nounderline abstract_t">Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000; 14:173.</a></li><li><a class="nounderline abstract_t">Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126:817.</a></li><li><a class="nounderline abstract_t">Macdonald JC, Karavellas MP, Torriani FJ, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 2000; 107:877.</a></li><li><a class="nounderline abstract_t">Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633.</a></li><li><a class="nounderline abstract_t">Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177:1182.</a></li><li><a class="nounderline abstract_t">Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285.</a></li><li><a class="nounderline abstract_t">Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001; 32:815.</a></li><li><a class="nounderline abstract_t">D'Amico R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 2005; 25:106.</a></li><li><a class="nounderline abstract_t">Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998; 177:770.</a></li><li><a class="nounderline abstract_t">Jabs DA, Martin BK, Forman MS, et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol 2001; 132:700.</a></li><li><a class="nounderline abstract_t">Martin BK, Ricks MO, Forman MS, et al. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis 2007; 44:1001.</a></li><li><a class="nounderline abstract_t">Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001; 183:333.</a></li><li><a class="nounderline abstract_t">Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010; 50:733.</a></li><li><a class="nounderline abstract_t">Jabs DA, Martin BK, Ricks MO, et al. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. J Infect Dis 2006; 193:1728.</a></li><li><a class="nounderline abstract_t">Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996; 114:23.</a></li><li><a class="nounderline abstract_t">Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000; 182:1765.</a></li><li><a class="nounderline abstract_t">Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs 2000; 9:207.</a></li><li><a class="nounderline abstract_t">Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133:475.</a></li><li><a class="nounderline abstract_t">Vitravene Study Group.. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:484.</a></li><li><a class="nounderline abstract_t">Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:467.</a></li><li><a class="nounderline abstract_t">Turner N, Strand A, Grewal DS, et al. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Frange P, Leruez-Ville M. Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl 2:S34.</a></li><li><a class="nounderline abstract_t">Ross SD, DiGeorge A, Connelly JE, et al. Safety of GM-CSF in patients with AIDS: a review of the literature. Pharmacotherapy 1998; 18:1290.</a></li><li><a class="nounderline abstract_t">Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.</a></li><li><a class="nounderline abstract_t">Ortega-Larrocea G, Espinosa E, Reyes-Terán G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS 2005; 19:735.</a></li><li><a class="nounderline abstract_t">Goldberg DE, Wang H, Azen SP, Freeman WR. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 2003; 87:853.</a></li><li><a class="nounderline abstract_t">Stewart MW. Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment. Curr Infect Dis Rep 2017; 19:47.</a></li><li><a class="nounderline abstract_t">Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125:292.</a></li><li><a class="nounderline abstract_t">Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina 2005; 25:633.</a></li><li><a class="nounderline abstract_t">Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm 1999; 7:215.</a></li><li><a class="nounderline abstract_t">Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129:634.</a></li><li><a class="nounderline abstract_t">Song MK, Azen SP, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:696.</a></li><li><a class="nounderline abstract_t">Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 2005; 6:136.</a></li><li><a class="nounderline abstract_t">Karavellas MP, Azen SP, MacDonald JC, et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21:1.</a></li><li><a class="nounderline abstract_t">Kosobucki BR, Goldberg DE, Bessho K, et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol 2004; 137:636.</a></li><li><a class="nounderline abstract_t">Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999; 83:540.</a></li><li><a class="nounderline abstract_t">Pathanapitoon K, Ausayakhun S, Kunavisarut P, et al. Blindness and low vision in a tertiary ophthalmologic center in Thailand: the importance of cytomegalovirus retinitis. Retina 2007; 27:635.</a></li><li><a class="nounderline abstract_t">Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis 2013; 57:1351.</a></li><li><a class="nounderline abstract_t">Sittivarakul W, Seepongphun U. Incidence Rates and Risk Factors for Vision Loss among AIDS-Related Cytomegalovirus Retinitis Patients in Southern Thailand. Ocul Immunol Inflamm 2018; 26:82.</a></li><li><a class="nounderline abstract_t">Ocieczek P, Barnacle JR, Gumulira J, et al. Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study. Open Forum Infect Dis 2019; 6:ofz439.</a></li><li><a class="nounderline abstract_t">Tun N, Smithuis FM, London N, et al. Mortality in patients with AIDS-related cytomegalovirus retinitis in Myanmar. Clin Infect Dis 2014; 59:1650.</a></li><li><a class="nounderline abstract_t">Lapere SRJ, Rice JC. Cytomegalovirus retinitis in Cape Town, South Africa: Clinical management and outcomes. S Afr Med J 2017; 107:514.</a></li><li><a class="nounderline abstract_t">Chakraborty A, Mahapatra T, Mahapatra S, et al. Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India. PLoS One 2015; 10:e0117466.</a></li><li><a class="nounderline abstract_t">Murray J, Hilbig A, Soe TT, et al. Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data. BMC Infect Dis 2020; 20:842.</a></li><li class="breakAll">World Health Organization. Model list  
of essential medicines. http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1 (Accessed on November 19, 2015).</li><li><a class="nounderline abstract_t">Tun N, London N, Kyaw MK, et al. CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar. J Int AIDS Soc 2011; 14:41.</a></li><li><a class="nounderline abstract_t">Heiden D, Saranchuk P, Tun N, et al. We urge WHO to act on cytomegalovirus retinitis. Lancet Glob Health 2014; 2:e76.</a></li></ol></div><div id="topicVersionRevision">Topic 3731 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on April 12, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16167292" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137552" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282490" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : AIDS and ophthalmology: the first quarter century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496411" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Local therapy for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9211677" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728878" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Human cytomegalovirus resistance to antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15819597" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565338" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Drugs for non-HIV viral infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948271" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1377475" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656826" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1345799" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9036797" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9036798" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9194724" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581429" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525435" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18052600" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194235" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232720" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419804" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2821465" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of cytomegalovirus retinitis with ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496303" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783947" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708288" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860006" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811078" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553789" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593001" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11262214" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229851" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821887" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498461" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704031" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342657" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120934" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100090" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cytomegalovirus resistance testing: pitfalls and problems for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16703517" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540847" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069251" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11060672" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Therapeutic developments in cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11931781" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11931782" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11931780" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30642941" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31023819" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7875151" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855329" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety of GM-CSF in patients with AIDS: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9456256" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821403" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12812884" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29046981" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9512145" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077362" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : HIV-associated retinopathy in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10611730" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immune recovery uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844056" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516810" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192248" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11217922" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059701" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Valganciclovir therapy for immune recovery uveitis complicated by macular edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216051" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of immune recovery vitritis with local steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558328" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Blindness and low vision in a tertiary ophthalmologic center in Thailand: the importance of cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899681" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323489" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Incidence Rates and Risk Factors for Vision Loss among AIDS-Related Cytomegalovirus Retinitis Patients in Southern Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723570" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25121775" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mortality in patients with AIDS-related cytomegalovirus retinitis in Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28604324" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cytomegalovirus retinitis in Cape Town, South Africa: Clinical management and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25679798" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33187478" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33187478" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21843351" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104662" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : We urge WHO to act on cytomegalovirus retinitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
